TY - JOUR
T1 - Alzheimers prevention initiative
T2 - A plan to accelerate the evaluation of presymptomatic treatments
AU - Reiman, Eric M.
AU - Langbaum, Jessica B.S.
AU - Fleisher, Adam S.
AU - Caselli, Richard J.
AU - Chen, Kewei
AU - Ayutyanont, Napatkamon
AU - Quiroz, Yakeel T.
AU - Kosik, Kenneth S.
AU - Lopera, Francisco
AU - Tariot, Pierre N.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2011
Y1 - 2011
N2 - There is an urgent need to find effective presymptomatic Alzheimers disease (AD) treatments that reduce the risk of AD symptoms or prevent them completely. It currently takes too many healthy people, too much money and too many years to evaluate the range of promising presymptomatic treatments using clinical endpoints. We have used brain imaging and other measurements to track some of the earliest changes associated with the predisposition to AD. We have proposed the Alzheimers Prevention Initiative (API) to evaluate investigational amyloid-modifying treatments in healthy people who, based on their age and genetic background, are at the highest imminent risk of developing symptomatic AD using brain imaging, cerebrospinal fluid (CSF), and cognitive endpoints. In one trial, we propose to study AD-causing presenilin 1 [PS1] mutation carriers from the worlds largest early-onset AD kindred in Antioquia, Colombia, close to their estimated average age at clinical onset. In another trial, we propose to study apolipoprotein E (APOE) ε4 homozygotes (and possibly heterozygotes) close to their estimated average age at clinical onset. The API has several goals: 1) to evaluate investigational AD-modifying treatments sooner than otherwise possible; 2) to determine the extent to which the treatments brain imaging and other biomarker effects predict a clinical benefit - information needed to help qualify biomarker endpoints for use in pivotal prevention trials; 3) to provide a better test of the amyloid hypothesis than clinical trials in symptomatic patients, when these treatments may be too little too late to exert their most profound effect; 4) to establish AD prevention registries needed to support these and other presymptomatic AD trials; and 5) to give those individuals at highest imminent risk of AD symptoms access to the most promising investigational treatments in clinical trials.
AB - There is an urgent need to find effective presymptomatic Alzheimers disease (AD) treatments that reduce the risk of AD symptoms or prevent them completely. It currently takes too many healthy people, too much money and too many years to evaluate the range of promising presymptomatic treatments using clinical endpoints. We have used brain imaging and other measurements to track some of the earliest changes associated with the predisposition to AD. We have proposed the Alzheimers Prevention Initiative (API) to evaluate investigational amyloid-modifying treatments in healthy people who, based on their age and genetic background, are at the highest imminent risk of developing symptomatic AD using brain imaging, cerebrospinal fluid (CSF), and cognitive endpoints. In one trial, we propose to study AD-causing presenilin 1 [PS1] mutation carriers from the worlds largest early-onset AD kindred in Antioquia, Colombia, close to their estimated average age at clinical onset. In another trial, we propose to study apolipoprotein E (APOE) ε4 homozygotes (and possibly heterozygotes) close to their estimated average age at clinical onset. The API has several goals: 1) to evaluate investigational AD-modifying treatments sooner than otherwise possible; 2) to determine the extent to which the treatments brain imaging and other biomarker effects predict a clinical benefit - information needed to help qualify biomarker endpoints for use in pivotal prevention trials; 3) to provide a better test of the amyloid hypothesis than clinical trials in symptomatic patients, when these treatments may be too little too late to exert their most profound effect; 4) to establish AD prevention registries needed to support these and other presymptomatic AD trials; and 5) to give those individuals at highest imminent risk of AD symptoms access to the most promising investigational treatments in clinical trials.
KW - Brain imaging
KW - apolipoprotein E
KW - biomarkers
KW - cerebral spinal fluid
KW - clinical trials
KW - early-onset Alzheimers disease
KW - late-onset Alzheimers disease
KW - presenilin 1
KW - presymptomatic Alzheimers disease
KW - surrogate markers
UR - http://www.scopus.com/inward/record.url?scp=80055034288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055034288&partnerID=8YFLogxK
U2 - 10.3233/JAD-2011-0059
DO - 10.3233/JAD-2011-0059
M3 - Article
C2 - 21971471
AN - SCOPUS:80055034288
VL - 26
SP - 321
EP - 329
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
SN - 1387-2877
IS - SUPPL. 3
ER -